Enliven Therapeutics (ELVN) affiliate notifies broker to offer 18,054 shares
Rhea-AI Filing Summary
Enliven Therapeutics filed a Form 144 reporting the proposed sale of 18,054 shares of Common Stock through Jefferies LLC, dated 06/17/2026. The notice lists three lots tied to option exercises: 7,090, 3,000, and 7,964 shares with exercise dates shown as 08/09/2022, 12/13/2024, and 03/04/2025, respectively.
The filing identifies Jefferies LLC at 520 Madison Ave as the broker-dealer and shows an aggregate value field of $768,197.70 on the cover line. The filing is a routine Section 16 disposition notice for resale of shares previously acquired by option exercise.
Positive
- None.
Negative
- None.
Insights
Form 144 documents a planned resale of shares by an insider or affiliate via broker-dealer.
The filing lists 18,054 shares offered for sale in three lots tied to prior option exercises dated 08/09/2022, 12/13/2024, and 03/04/2025
Timing and execution details are not provided here; subsequent transactional reports (Forms 4 or broker confirmations) will show actual sales and proceeds.
This is an administrative resale notice; it does not change Enliven's disclosed financials or guidance.
The filing names Jefferies LLC as the broker and shows an aggregate value line of $768,197.70 on the cover. That figure appears on the cover but the exact per-share sale prices are not listed.
Actual market impact depends on execution size and timing, neither of which are specified in this excerpt.